We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

158 hedge funds and large institutions have $3.61B invested in Loxo Oncology, Inc in 2018 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 48 increasing their positions, 55 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 15

32% more capital invested

Capital invested by funds: $2.74B → $3.61B (+$875M)

12% more funds holding

Funds holding: 141158 (+17)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

13% less repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 55

52% less call options, than puts

Call options by funds: $16.8M | Put options by funds: $34.9M

Holders
158
Holders Change
+17
Holders Change %
+12.06%
% of All Funds
3.62%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.14%
New
36
Increased
48
Reduced
55
Closed
15
Calls
$16.8M
Puts
$34.9M
Net Calls
-$18M
Net Calls Change
-$18.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$24.7M +$960K +9,030 +4%
Balyasny Asset Management
27
Balyasny Asset Management
Illinois
$24.5M -$18M -169,295 -44%
UBS AM
28
UBS AM
Illinois
$23M -$1.28M -12,026 -6%
Deutsche Bank
29
Deutsche Bank
Germany
$22.7M +$7.24M +68,050 +53%
CS
30
Credit Suisse
Switzerland
$21.5M +$7.23M +67,930 +58%
VOYA Investment Management
31
VOYA Investment Management
Georgia
$21.4M -$15.3M -144,139 -44%
DCM
32
DAFNA Capital Management
California
$20.9M -$12.2M -114,463 -39%
OM
33
Opaleye Management
Massachusetts
$20.7M +$330K +3,100 +2%
PAMU
34
Pictet Asset Management (UK)
United Kingdom
$19.9M -$5.15M -48,463 -22%
Goldman Sachs
35
Goldman Sachs
New York
$19.7M +$6.93M +65,133 +61%
Renaissance Technologies
36
Renaissance Technologies
New York
$15.8M +$14.6M +137,300 New
Bank of New York Mellon
37
Bank of New York Mellon
New York
$14.1M +$1.84M +17,298 +16%
BNP Paribas Asset Management
38
BNP Paribas Asset Management
France
$13.8M +$12.7M +119,640 New
Charles Schwab
39
Charles Schwab
California
$12.8M +$315K +2,960 +3%
Axa
40
Axa
France
$11.9M +$397K +3,728 +4%
Alyeska Investment Group
41
Alyeska Investment Group
Illinois
$10.5M -$657K -6,178 -6%
FCM
42
Frontier Capital Management
Massachusetts
$9.96M +$9.18M +86,302 New
AIC
43
AWM Investment Company
New York
$9.81M
Invesco
44
Invesco
Georgia
$9.28M -$9.26M -87,099 -52%
RPAM
45
Rhenman & Partners Asset Management
Sweden
$8.65M -$1.63M -15,280 -17%
KBC Group
46
KBC Group
Belgium
$8.57M +$7.9M +74,261 New
AAMU
47
Amundi Asset Management US
Massachusetts
$8.55M -$685K -6,438 -8%
Morgan Stanley
48
Morgan Stanley
New York
$8.48M +$99.6K +936 +1%
CS
49
Candriam SCA
Luxembourg
$8.31M -$2.02M -19,000 -21%
Macquarie Group
50
Macquarie Group
Australia
$7.87M -$77.3K -727 -1%

LOXO Hedge Fund Activity: Q1 2018 in Review

158 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q1 2018, worth a combined $3.61B — up 32% from $2.74B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new LOXO positions and 15 closed out — a net gain of 21 holders — while 48 added to existing stakes and 55 trimmed.

The largest buyer was Boxer Capital, opening a new position worth an estimated $42.5M. The largest seller was OrbiMed, cutting an estimated $9.91B.

  • 158 institutional investors held Loxo Oncology, Inc (LOXO) as of Q1 2018, up from 141 in Q4 2017.
  • Funds reported $3.61B of Loxo Oncology, Inc stock for Q1 2018, up 32% quarter-over-quarter.
  • 36 funds opened new Loxo Oncology, Inc positions in Q1 2018 and 15 closed out, a net change of +21 holders.
  • The largest Loxo Oncology, Inc buyer in Q1 2018 was Boxer Capital, an estimated $42.5M added.
  • The largest Loxo Oncology, Inc seller in Q1 2018 was OrbiMed, an estimated $9.91B sold.

Based on aggregated 13F filings for Q1 2018.